Ann: Agreement with C14 Consulting Group, page-5

Biotron Limited, a Sydney-based biotech company, announced its partnership with C14 Consulting Group LLC (C14), a U.S.-based consultancy, to advance its antiviral programs, including its lead clinical asset, BIT225.

Key Points:

1. C14's Role: C14 will support Biotron by refining its commercialization strategy and providing business development assistance. C14 specializes in securing licensing agreements, joint ventures, and commercialization opportunities for pharmaceutical assets, leveraging strong industry relationships and market expertise.

2. Biotron’s Focus: The company aims to commercialize its antiviral portfolio, including:

   • BIT225: Under clinical development for HIV-1 and COVID-19.
   • Preclinical programs targeting Hepatitis B Virus (HBV).
   • Additional early-stage programs aimed at viroporins, viral proteins crucial to the life cycle of viruses like Coronavirus, Dengue, Ebola, and others.

3. Strategic Alignment: The agreement includes project and retainer fees along with an outcome-based success model to align the interests of both parties in achieving commercial outcomes.

4. Statement from Leadership: Biotron's Managing Director, Michelle Miller, emphasized the importance of leveraging C14's expertise to efficiently commercialize their assets, backed by robust clinical and preclinical data.
   
   How long have they known about this!! The Options only expired last week, and the AGM is tomorrow.
   
   Useless